Enhancin

PreclinicalSmall molecule

UUniversity of Nairobi

Enhancin is one of 5 small molecule programs targeting Tonsillectomy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TonsillectomyCompleted

TonsillectomyPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Tonsillectomy

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

1 2

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 3

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1 4

Antibiotic

Pfizer

Preclinical

1 5

Enhancin

UUniversity of Nairobi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tonsillectomy1 trial

Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.

Completed·UUniversity of Nairobi·N/A·NCT01267942·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enhancin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enhancin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enhancin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Nairobi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Nairobi

Enhancin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tonsillectomy1 trial

References

Drug Info

Quick Facts

Related News